Plain-English translation of NCT07367282 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether Faricimab, a new injectable medicine, can help treat wet age-related macular degeneration—a serious eye condition that causes vision loss in older adults. You would receive monthly injections into your eye for the first four months, then continue treatment based on how your eye responds. The goal is to see if this medication can slow or stop vision loss and help you maintain your eyesight.
Wet age-related macular degeneration damages the center of your vision and can lead to severe vision loss. While some treatments exist, doctors want to test whether this new medication might work better or offer patients more flexibility in how often they need treatment.
You likely qualify if…
You likely don't qualify if…
You would visit the study site about 10 times over approximately one year. You would receive 4 monthly injections of the medication into your eye during the first phase, then continue with additional injections spaced further apart based on how your eye responds. Between visits, doctors would check your vision and take eye images to monitor your progress and decide when your next injection should be.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
South Korea